LIXTE Files Q1 10-Q, Expands Ovarian Cancer Study with GSK’s Dostarlimab
LIXT•LIXTE filed its Q1 2026 Form 10-Q detailing advances in its lead compound LB-100, which showed a favorable safety profile in combination with GSK’s dostarlimab and prompted expansion of its ovarian cancer trial. The company also integrated Liora Technologies Europe and advanced its LIGHT proton therapy platform.
1. Q1 2026 Filing and Report Highlights
LIXTE filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, providing updated operational and pipeline details. The report outlines progress on clinical programs, integration efforts and strategic initiatives undertaken during the period.
2. Expansion of LB-100 Ovarian Cancer Trial
Following a study confirming LB-100’s favorable safety profile when combined with GSK’s dostarlimab, LIXTE expanded its ovarian cancer trial, enrolling additional patients to evaluate efficacy in tumors with PP2A function loss. Preliminary results presented at a gynecological oncology conference showed promising synergistic activity.
3. Liora Technologies Europe Integration and Summit
LIXTE advanced integration of its newly acquired Liora Technologies Europe, accelerating deployment of the LIGHT proton therapy system across key markets. The company also hosted its inaugural Good Health: Mind, Body & Soul Summit to promote health equity and align community outreach with its oncology development strategy.
